| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_604e07c32377cab416660b10fd8f494c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 |
| filingDate |
1994-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2f629a47eb2d4862f6955ad915d01e8 |
| publicationDate |
1994-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9423755-A1 |
| titleOfInvention |
Novel methods and compositions for the treatment of ras-activated cancer with heterotypic anti-raf antisense oligonucleotides |
| abstract |
In accordance with the present invention there is provided a method for killing cancer cells expressing an activated ras oncogene by contacting the ras-activated cancer cells in vivo or in vitro with a cytotoxically-effective amount of a heterotypic antisense oligonucleotide or combination of antisense oligonucleotides, or pharmaceutically-effective analogs thereof, which have base sequences complementary to a sequence of the DNA or transcribed messenger RNA of a raf gene also present in the same cancer cells. The present invention also provides novel methods for treating an individual who has ras-activated cancer. This treatment involves the use of heterotypic antisense oligonucleotide therapies, in which a cytotoxically-effective amount of a preparation containing an anti-raf antisense oligonucleotide, or combination of selected anti-raf antisense oligonucleotides, or one or more pharmaceutically-effective analogs thereof, is administered as specific drug therapy of cancers expressing an activated ras oncogene. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9532987-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8796250-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8618141-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9639415-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2733500-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6391636-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6957148-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0161030-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8841330-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0161030-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9732604-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9634008-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8124630-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7897623-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8242147-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5981731-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5744460-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7838541-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7262173-B2 |
| priorityDate |
1993-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |